Medtronic PLC $MDT Shares Acquired by Millington Financial Advisors LLC

Millington Financial Advisors LLC raised its stake in shares of Medtronic PLC (NYSE:MDT) by 5.3% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 24,123 shares of the medical technology company’s stock after purchasing an additional 1,220 shares during the period. Millington Financial Advisors LLC’s holdings in Medtronic were worth $2,220,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in MDT. Gilbert & Cook Inc. lifted its stake in shares of Medtronic by 1.9% in the 2nd quarter. Gilbert & Cook Inc. now owns 6,103 shares of the medical technology company’s stock valued at $532,000 after purchasing an additional 114 shares in the last quarter. Red Spruce Capital LLC grew its stake in Medtronic by 0.5% in the second quarter. Red Spruce Capital LLC now owns 23,707 shares of the medical technology company’s stock worth $2,067,000 after purchasing an additional 118 shares in the last quarter. Certior Financial Group LLC lifted its holdings in Medtronic by 3.7% during the 1st quarter. Certior Financial Group LLC now owns 3,450 shares of the medical technology company’s stock worth $310,000 after buying an additional 122 shares during the last quarter. PrairieView Partners LLC grew its position in shares of Medtronic by 3.6% in the 2nd quarter. PrairieView Partners LLC now owns 3,726 shares of the medical technology company’s stock worth $324,000 after acquiring an additional 128 shares in the last quarter. Finally, Baker Avenue Asset Management LP boosted its position in Medtronic by 3.1% during the 1st quarter. Baker Avenue Asset Management LP now owns 4,558 shares of the medical technology company’s stock valued at $410,000 after purchasing an additional 136 shares during the period. 82.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Cowen reaffirmed a “buy” rating on shares of Medtronic in a report on Friday, November 14th. Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. The Goldman Sachs Group set a $111.00 price objective on shares of Medtronic and gave the stock a “neutral” rating in a research report on Wednesday, November 19th. Stifel Nicolaus upped their target price on Medtronic from $90.00 to $105.00 and gave the company a “hold” rating in a report on Thursday, October 9th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $110.00 price objective on shares of Medtronic in a research report on Wednesday, November 19th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $110.44.

Medtronic Stock Down 0.5%

Shares of NYSE MDT opened at $104.53 on Friday. Medtronic PLC has a 52-week low of $79.29 and a 52-week high of $106.33. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.50 and a current ratio of 2.01. The business has a fifty day moving average of $96.06 and a two-hundred day moving average of $91.66. The stock has a market cap of $134.00 billion, a PE ratio of 28.79, a PEG ratio of 2.42 and a beta of 0.77.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.31 by $0.05. The firm had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The firm’s quarterly revenue was up 6.6% on a year-over-year basis. During the same period last year, the firm posted $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 8,605 shares of Medtronic stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the transaction, the executive vice president owned 35,615 shares in the company, valued at approximately $3,261,621.70. The trade was a 19.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.26% of the stock is owned by corporate insiders.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.